Last update 01 Nov 2024
HBG gene modified autologous CD34+ hematopoietic stem cells(Guangzhou Ruifeng)
Last update 01 Nov 2024
Overview
Basic Info
Drug Type Gene therapy, Hematopoietic stem cell therapy |
Synonyms |
Target |
Mechanism HBG gene stimulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with HBG gene modified autologous CD34+ hematopoietic stem cells(Guangzhou Ruifeng)A Safety and Efficacy Study Evaluating RM-001 in Subjects with Transfusion-Dependent ß-Thalassemia
评价自体CRISPR-Cas9编辑的CD34阳性细胞（RM-001细胞注射液）治疗输血依赖型β-地中海贫血症安全性和有效性的单臂、开放、单剂量、多中心的Ⅰ/Ⅱ期临床研究
[Translation] A single-arm, open-label, single-dose, multicenter Phase I/II clinical study to evaluate the safety and efficacy of autologous CRISPR-Cas9-edited CD34-positive cells (RM-001 cell injection) in the treatment of transfusion-dependent β-thalassemia
The Safety and Efficacy Evaluation of RM-001 for the Treatment of Transfusions Dependent ß-Thalassaemia Major in Clinical Trials
100 Clinical Results associated with HBG gene modified autologous CD34+ hematopoietic stem cells(Guangzhou Ruifeng)
Login to view more data
100 Translational Medicine associated with HBG gene modified autologous CD34+ hematopoietic stem cells(Guangzhou Ruifeng)
Login to view more data
100 Patents (Medical) associated with HBG gene modified autologous CD34+ hematopoietic stem cells(Guangzhou Ruifeng)
Login to view more data
100 Deals associated with HBG gene modified autologous CD34+ hematopoietic stem cells(Guangzhou Ruifeng)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Transfusion-dependent Beta Thalassemia | Phase 1 | CN | 15 Dec 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 16 | (myljdjbfpf) = czxgqhedwu mtbzannarn (qikehfmcfe ) Met View more | Positive | 14 May 2024 | |||
Not Applicable | 7 | (jesgjlmxtl) = imgrvpuhto mnbncthnmp (etcjtnmzox ) View more | - | 11 Dec 2023 | |||
Not Applicable | 2 | (gmseswiyds) = dqzvonfhmj wxopppmeee (iddqkfpybc ) | Positive | 12 May 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free